

1 **A single dose SARS-CoV-2 simulating particle vaccine induces potent**
2 **neutralizing activities**

3 Di Yin^{1,#}, Sikai Ling^{1,#}, Xiaolong Tian^{2,#}, Yang Li¹, Zhijue Xu¹, Hewei Jiang¹, Xue Zhang¹, Xiaoyuan
4 Wang³, Yi Shi⁴, Yan Zhang¹, Lintai Da¹, Sheng-ce Tao¹, Qunjun Wang⁵, Jianjiang Xu⁶, Tianlei
5 Ying^{2,*}, Jiayu Hong^{6,7,*}, and Yujia Cai^{1,*}

6 ¹*Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems*
7 *Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, China.*

8 ²*MOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, School of Basic Medical*
9 *Sciences, Fudan University, Shanghai 200032, China.*

10 ³*BD Gene Therapeutics, Shanghai 200240, China.*

11 ⁴*Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders,*
12 *Shanghai Jiao Tong University, Shanghai 200030, China.*

13 ⁵*National Beijing Center for Drug Safety Evaluation and Research, State Key Laboratory of Medical*
14 *Countermeasures and Toxicology, Institute of Pharmacology and Toxicology, Academy of Military*
15 *Sciences, Beijing 100850, China.*

16 ⁶*Department of Ophthalmology and Vision Science, Shanghai Eye, Ear, Nose and Throat Hospital,*
17 *Fudan University, Shanghai 200031, China.*

18 ⁷*Department of Ophthalmology, The Affiliated Hospital of Guizhou Medical University, Guiyang*
19 *550004, China.*

20 [#]These authors contributed equally.

21 ^{*}**For correspondence:**

22 *TY: Phone: 86-021-54237761, tlying@fudan.edu.cn*

23 *JH: Phone: 86-021-64377134, jiayu_hong@163.com*

24 *YC: Phone: 86-021-34208571, yujia.cai@sjtu.edu.cn*

25

26 **Running title:** A SARS-CoV-2 vaccine induces neutralizing antibody

27 **Keywords:** SARS-CoV-2; vaccine; neutralizing antibody; COVID-19

1 ABSTRACT

2 **Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome**
3 **coronavirus 2 (SARS-CoV-2) for which a vaccine is urgently needed to control its spreading.**
4 **To facilitate the representation of a native-like immunogen without being infectious, here, we**
5 **reported a SARS-CoV-2 vaccine candidate (designated ShaCoVacc) by incorporating spike-**
6 **encoding mRNA inside and decorating spike protein on the surface of the virus simulating**
7 **particles (VSPs) derived from lentiviral particles. We characterized the mRNA copy number,**
8 **glycosylation status, transduction efficiency, and innate immune property of the new vaccine**
9 **platform. Importantly, we showed the ShaCoVacc induced strong spike-specific humoral**
10 **immune responses and potent neutralizing activities by a single injection. Additionally, we**
11 **disclosed the epitopes of spike-specific antibodies using peptide microarray and revealed**
12 **epitopes susceptible to specific neutralizing antibodies. These results support further**
13 **development of ShaCoVacc as a candidate vaccine for COVID-19 and VSP may serve as a new**
14 **vaccine platform for emerging infectious diseases.**

15

16 The coronavirus disease-19 (COVID-19) has been rapidly becoming a globe pandemic since its first
17 report in Wuhan, China, in the December of 2019¹. The disease is caused by Severe Acute Respiratory
18 Syndrome Coronavirus 2 (SARS-CoV-2) which was effectively transmitted from human to human,
19 with influenza-like symptoms ranging from mild disease to severe lung injury and multi-organ failure,
20 eventually causing death, especially in aged patients with co-morbidities^{2,3}. Vaccines are considered
21 to be one of the most effective ways to terminate the pandemic and help to restore the global
22 economy^{4,5}. By May 12, at least six SARS-CoV-2 vaccine candidates have entered the clinical stage
23 basing on different platforms, i.e. mRNA, adenovirus, lentivirus, and plasmid DNA⁶. However,
24 published information regarding the neutralizing efficacy of each vaccine is still very limited except
25 an inactivated vaccine for which, however, multiple vaccinations are needed to get high EC50 titer^{7,8}.

26 In the past decades, numerous vaccine platforms have been approved for markets or clinical trials.
27 Live attenuated vaccines are weakened pathogens that induce strong humoral and cellular immune
28 response but also with infection risks especially for immune-compromised people^{9,10}. Inactivated
29 vaccines are killed pathogens with intact structure and destroyed genetic materials – therefore, less
30 risky, but also less efficacy^{9,10}. Protein subunit vaccine, viral vector vaccine, and nucleic acid vaccine
31 (DNA and mRNA) are generally safe, but difficult to reflect the conformational structure of viral

1 immunogen in its nature^{11,12}. Virus-like particles (VLPs) are hulk particles with the unique ability to
2 present viral spikes in their natural conformation and elicit conformation-dependent neutralizing
3 antibodies¹³⁻¹⁶. A closer mimicking of a pathogen would be a VLP with spikes on its surface and
4 antigen-encoding nucleic acids inside. It is still unknown which vaccine platform will actually work
5 for SARS-CoV-2, making the development of new vaccine platforms of great importance. As
6 neutralizing antibodies have been detected in convalescents of COVID-19¹⁷⁻²⁰, a SARS-CoV-2
7 simulating vaccine may present the antigens to the immune systems in much the same way that it
8 would be presented by an authentic virus, thereby provoking a similar effective immune response.

9 In this study, we designed a candidate vaccine by encapsulating spike within and decorated onto the
10 surface of virus simulating particles (VSPs) derived from lentiviral particles in the form of mRNA
11 and protein, respectively, simulating the wild-type SARS-CoV-2. We hypothesized this could be
12 achieved by co-expression of a full-length spike during the production of mRNA-carrying lentiviral
13 particle which we have recently developed for time-restricted gene editing (Manuscript under
14 revision). To package the full-length spike mRNA into VSPs, we designed a spike construct
15 expressing the spike protein with 6X MS2 stem loop repeats on its transcripts which would allow the
16 spike mRNA to be packaged into VSPs via interaction with MS2 coat fused GagPol (Fig. 1a).
17 Meanwhile, as an envelope protein, the spike protein would automatically assemble into the
18 membrane of virus simulating particles (Fig. 1b).

19 To make sure high transcription and translation in the producer cells, we used a CMV promoter to
20 drive spike expression (Fig. 1a). In addition, the spike sequence was codon-optimized and equipped
21 with a signal peptide from the human heavy chain of IgE to boost translation and immunogenicity
22 (Fig. 1a)⁴. We also introduced two proline substitution mutations in the S2 of spike sequence which
23 have been reported to increase the expression of spike and enhance the production of neutralizing
24 antibodies (Fig. 1a)^{21,22}. The resulting spike transcript contains a MS2 stem loop between the stop
25 codon and the polyA sequence so that it could be packaged into lentiviral particles via direct
26 interaction with its cognate MS2 coat protein localized in the N-terminus of GagPol polyprotein. As
27 VSV-G coated lentiviruses are efficiently taken up by antigen-presenting cells and show the high
28 immunogenicity of antigens²³, we also included the VSV-G encoding plasmid (pMD.2G) in the
29 production process so that the surface of resulting VSPs will be covered by both spike and VSV-G
30 (Fig. 1b).

31 To examine if spike mRNA has been packaged into lentiviral particle as designed, we performed RT-
32 qPCR and found 3 or 4 copies of spike mRNA on average for each VSP (Fig. 1c). To verify whether

1 spike proteins have been assembled into VSPs and their glycosylation status, we performed Western
2 blot on the lysates of VSP with integration-defective lentiviruses (IDLVs) as controls (Fig. 1d). We
3 found successful decoration of spikes both with and without mutations on the VSPs while more
4 mutant spikes could be loaded. As glycosylation impacts the immunogenicity and immunodominance
5 of a vaccine²⁴, we examined the glycosylation status of the spike on the surface of VSPs. Notably,
6 the S2 bands shifted downwards after PNGase F treatment indicating that the spikes on VSPs were
7 modified by N-linked glycosylations consistent with the recent finding for SARS-CoV-2 revealed by
8 mass spectrometric approach (Fig. 1d)²⁵. Next, we transduced VSPs to 293T cells and evaluated the
9 expression of spikes. We harvested the cells 36 hr postinfection without boiling the samples for
10 Western blot to avoid potential aggregation of the spike protein. 293T cells were not infected by
11 SARS-CoV-2 unless supplemented with hACE2²⁶. Here, we still observed the expression of spikes
12 in 293T cells from VSPs suggesting that VSV-G were co-assembled into VSPs, thereby, broadened
13 their tropism (Fig. 1e). We found two major bands for spikes which were likely glycosylated full-
14 length singlet spike and its dimeric/trimeric forms (Fig. 1e). Additionally, we confirmed the
15 expression of spike using confocal analysis of transfected or transduced 293T cells (Fig. 1f). To
16 examine the innate immune property of VSP, we used THP-1 derived macrophages as a model of
17 nucleic sensing and found no significant increase of the type I interferon (IFN) and IFN-stimulated
18 genes ISG-15, and retinoic acid-inducible gene I (RIG-I) (Fig. 1g-i). As VSP-spike-mut incorporates
19 both mRNA and protein of spike more efficiently than the wild-type counterpart, we therefore chose
20 it as a vaccine candidate (designated ShaCoVacc) for in vivo evaluation.

21 To access the immunogenicity of ShaCoVacc, we injected the vaccine candidate to C57BL/6J mice
22 (n=6 for each group) via footpad (Fig. 2a). We performed enzyme-linked immunosorbent assay
23 (ELISA) using the sera from mice two weeks after vaccination to get access to the spike-specific IgG.
24 As shown in Fig. 2b, we observed significant elicitation of the spike-specific IgG. To evaluate the
25 production of neutralizing antibodies, we performed the neutralizing assay using spike pseudotyped
26 HIV which encodes firefly luciferase - a well-established pseudovirus neutralization assay²⁷.
27 Interestingly, a single injection of ShaCoVacc in our study induced an immediate and potent immune
28 responses against SARS-CoV-2 in contrast to an inactivated vaccine which required at least two or
29 three doses of injections (Fig. 2c)⁸. We also adopted the spike pseudotyped lentivirus which encodes
30 GFP to transduce Huh-7 cells. We found pre-incubation with 1:40 diluted sera from vaccinated mice
31 almost completely abolished the fluorescence which was evident for placebo groups and positive
32 controls (Fig. 2d) in line with Fig. 2c. Interestingly, sera from the vaccinated mice did not inhibit the

1 transduction of VSV-G pseudotyped lentivirus in Huh-7 cells indicating the neutralizing antibody is
2 spike-specific (Fig. 2d). T cell immune response is usually important for the function of vaccines to
3 control virus infection²⁸. However, in case of COVID-19, overproduction of cytokines has been
4 correlated with the disease severity²⁹. Therefore, cellular immunity must be cautious for any SARS-
5 CoV-2 vaccines. Here, we evaluated the T cell immune response here by simulating splenocytes with
6 a pool of spike-derived peptides. We did not find increased expression of IFN- γ and IL-2 suggesting
7 spike-specific cellular immune response was insignificant for ShaCoVacc (Fig. 2e-f). This is line
8 with a recent study with an inactivated SARS-CoV-2 vaccine which showed protection effects, but
9 found no notable changes in the percentages of lymphocytes and key cytokines in vaccinated
10 macaques⁸. Additionally, no weight loss caused by ShaCoVacc was found during the course of
11 vaccination suggesting no evident toxicity (Supplementary Fig. 1).

12 To dissect the linear epitope profile of the spike-specific antibodies in the vaccinated mice, we used
13 a newly developed peptide microarray which contains short peptides covering the full-length of a
14 spike. We found varying intensities of signals corresponding to certain spike peptides for the
15 vaccinated group while no signal was observed for the placebo treated mice (Fig. 2g). We also
16 quantified the signal intensity for antibodies against the S1 domain and receptor-binding domain
17 (RBD), respectively. The sera from vaccinated mice elicited significantly high signals for both
18 domains echoing our ELISA analysis of spike-specific antibodies and neutralizing assays (Fig. 2h).
19 To access to the panorama of epitopes, we made a heat map for of all vaccinated mice and found
20 epitope profiles for each vaccinated mouse were distinct (Fig. 2i and Supplementary Table 1).
21 However, we also found three epitopes (S2-22, S2-76, and S2-83) that were common for 66.7% of
22 the vaccinated mice. Interestingly, the S2-22 epitope also appeared in the majority of the
23 convalescents uncovered by our peptide microarray (manuscript in preparation). Antibody against
24 this epitope pulled from sera of convalescents has shown potent neutralizing activity¹⁷. Notably, S2-
25 76 and S2-83 epitopes are conserved epitopes and shared by SARS-CoV and SARS-CoV-2
26 (Supplementary Fig. 2).

27 We further revealed five neutralization epitopes locating on RBD, the domain responsible for the host
28 receptor recognition. The identified antibodies targeting these sites, therefore, can potentially block
29 the virus entry efficiently (Fig. 2j). Notably, former studies have shown that the murine
30 monoclonal/polyclonal antibodies that exhibit apparent binding to RBD from SARS-CoV exert no
31 neutralization activities against SARS-CoV-2, likely caused by their distinct structural features³⁰. Our
32 findings thus pinpoint the key structural motifs in SARS-CoV-2-RBD that are susceptible to specific

1 neutralizing antibodies. Interestingly, we also identified S2-83 epitope (N1178-V1189) locating on
2 the HR2 region, which undergoes a dramatic refolding process during virus entry, leading to the
3 formation of a six-helix bundle structure that finally drives membrane fusion (Fig. 2h). Considering
4 the critical role of HR2 and its high sequence conservation among different coronaviruses
5 (Supplementary Fig. 2), it is conceivable that antibody targeting to HR2 may potentially induce a
6 broad neutralizing activity against various coronaviruses.

7 In compensation to the traditional vaccine platforms, our study provided a new vaccine platform by
8 simulating coronavirus surface protein and internal nucleic acids, therefore, combining features of
9 inactivated vaccines and mRNA vaccines. Due to the limited resource to SARS-CoV-2, we are
10 currently not able to re-challenge the vaccinated animals with an authentic virus. As the VSP platform
11 is based on lentiviral GagPol and no transfer vector is involved, it will not produce insertional and
12 replication competent lentiviruses. Additionally, the large-scale production and quality standard of
13 lentivirus that has been developed in CAR-T industry may facilitate the accessibility of VSP vaccine
14 to general populations. We further revealed the epitope profiles of vaccinated mice and the epitopes
15 susceptible to specific neutralizing antibodies, which may facilitate drug and antibody development.

16

17 **METHODS**

18 **Cell cultures**

19 293T and Huh-7 cells were cultured in DMEM (Gibco, USA) supplemented with 10% fetal bovine
20 serum (Gibco, USA) and 1% penicillin/streptomycin (P/S) (Thermo Fisher Scientific, USA). Primary
21 splenocytes and THP-1 cells were cultured in RPMI 1640 (Gibco, USA) with 10% fetal bovine serum
22 (Gibco, USA). THP-1 cells were differentiated into macrophage-like cells with 150 nM phorbol 12-
23 myristate 13-acetate (PMA) (Sigma) before the experiment.

24

25 **Plasmids**

26 pCCL-PGK-spike-flag and pCCL-PGK-spike-mut-flag were constructed by replacing the GFP gene
27 in pCCL-PGK-eGFP with spike or mutant spike (K1003P and V1004P) gene. pCMV-spike-mut-
28 6XMS2, pCMV-spike-6XMS2-flag, pCMV-spike-mut-6XMS2-flag were generated by inserting
29 6XMS2 stem loop repeats between the stop codon of spike or mutant spike gene and polyA sequence
30 while the whole expression cassette is under the control of CMV promoter.

31

32 **Production of VSP, IDLVs, and pseudovirus**

1 VSP, IDLV, and pseudovirus were produced by 293T cells in 15-cm dishes. Cells were seeded in the
2 15-cm dish at a density of 10^7 /dish 24 hr before calcium phosphate transfection. The media were
3 refreshed 12 hr after transfection. 48 hr and 72 hr post-transfection, supernatants were filtered through
4 a 0.45- μ m filter (Millipore) and ultracentrifuged at 4°C for 2 hr. Pellets were re-suspended in PBS
5 and stored at -80°C. To produce GFP-expressing spike pseudovirus and IDLV (IDLV-spike or
6 IDLV-spike-mut), cells were transfected with 9.07 μ g pMD.2G (or corresponding spike plasmids),
7 7.26 μ g pRSV-Rev, 31.46 μ g pMDlg/pRRE-D64V, 31.46 μ g pCCL-PGK-eGFP (or pCCL-PGK-
8 spike-flag or pCCL-PGK-spike-mut-flag). To produce VSP-spike (or VSP-spike-mut), cells were
9 transfected with 9.07 μ g pMD.2G, 31.46 μ g pMS2M-PH-gagpol-D64V, 31.46 μ g pCMV-spike-
10 6XMS2, or pCMV-spike-mut-6XMS2, or their flag tag versions. To produce GFP-expressing spike
11 pseudovirus, cells were transfected with 9.07 μ g pCMV-spike, 7.26 μ g pRSV-Rev, 31.46 μ g
12 pMDlg/pRRE and 31.46 μ g pCCL-PGK-eGFP. To produce luciferase-encoding spike pseudovirus,
13 293T cells were transfected with 20 μ g pcDNA3.1-SARS-Cov2-spike and 20 μ g pNL4-3.luc.RE.

14

15 **Western blot**

16 To detect spike protein associated with VSP or IDLV, we use Western Blot to detect spike protein
17 with/without treatment of PNGase F (NEB). 100 ng particles were incubated with Glycoprotein
18 Denaturing Buffer at 98°C for 10 min. After adding GlycoBuffer 2 and NP-40 (10%), the mixtures
19 were incubated with/without PNGase F at 37°C for 2 hr. Mixtures were then incubated with SDS
20 loading buffer (Beyotime Biotechnology) before sample loading. To detect spike protein expressed
21 in cells, 293T cells were lysed in RIPA 36 hr after transfected with VSP or IDLV. The lysates were
22 incubated with SDS loading buffer supplemented with 2.5% β -Mercaptoethanol at 37°C for 30 min
23 without boiling. The proteins were separated by SDS-polyacrylamide gel electrophoresis and
24 transferred to the PVDF membrane. The membrane was blocked by 5% fat-free milk dissolved in
25 TBS/0.05% Tween-20 for 1 hr then cut off according to the marker and incubated with anti-flag
26 monoclonal antibody (Sigma) overnight at 4°C. The membranes were incubated with anti-mouse
27 secondary antibodies (Cell Signaling Technology) for 1 hr at room temperature. Proteins were
28 visualized by hypersensitive ECL chemiluminescence (Beyotime Biotechnology).

29

30 **Quantitative PCR**

31 To detected spike mRNA numbers carried by VSP, total RNAs from all samples were extracted using
32 the Viral DNA/RNA extraction kit (TaKaRa) followed by cDNA synthesization using the HiScript

1 Q RT SuperMix for qPCR (Vazyme, China) according to the manufacturer's protocol. RT-qPCR was
2 performed using qPCR SYBR Green Master Mix (Vazyme) following the manufacturer's protocol.
3 Plasmid pLV-PGK-S-mut diluted into copies of 10^3 , 10^4 , 10^5 , 10^6 , 10^7 per microliter were used to
4 make a standard curve for absolute quantification. Primer sequences are as follows, forward primer:
5 5'-ACAGATGAGATGATCGCCCAG-3', reverse primer: 5'-TCTGCATGGCGAAAGGGATC-3'.

6

7 **Mice**

8 6-8 weeks old, male, specific-pathogen-free (SPF) C57BL/6 mice were inoculated with VSP, IDLV,
9 or PBS by foot-pad injection. Animals were sacrificed by cervical dislocation under isoflurane. The
10 animal study has complied with the guidelines of the Institutional Animal Care and Use Committee
11 (IACUC) of the Shanghai Jiao Tong University.

12

13 **Splenocytes isolation**

14 Spleens were removed aseptically, placed in RPM 1640 medium, gently homogenized, and passed
15 through the cell strainer (Jet Bio-Filtration) to generate a single-cell suspension. Erythrocytes were
16 rapidly washed and lysed by the RBC lysis buffer (Sangon Biotech), and the splenocytes were
17 resuspended in 1mL RPMI 1640 medium.

18

19 **ELISA**

20 HIV p24 ELISA (Beijing Biodragon Immunotechnologies) was used to measure the p24 level of the
21 lentiviral particles according to the manufacturer. To detect SARS-CoV-2-spike specific antibodies
22 *in vivo*, serum from the animals were used to test the spike-specific IgG by Mouse IgG ELISA (Bethyl)
23 with a few modifications. 200 ng recombinant spike proteins were coated in 96-well ELISA plates
24 overnight at 4°C in a carbonating buffer (pH 9.5). The plates were blocked with PBS containing 0.05%
25 Tween 20 (PBS-T) and 2% bovine serum albumin (BSA) for 1 hr. Serum samples were diluted 1: 4
26 using PBS incubated for two hours, then washed and test follow the manufacturer's instructions. To
27 find the involvement of cellular immunity, the cytokine production in the splenic cells upon treatment
28 of spike peptides *in vitro* was measured. For the IFN- γ and IL-2 assay, the splenocytes were plated
29 in a 96-well plate at a density of 5×10^5 cells/200 μ L. Cells were incubated with a pool of SARS-CoV-
30 2 spike peptides of 1 μ g/mL final concentrations for each peptide for 24 hr, or 5 μ g/mL concanavalin
31 A (ConA) (Sigma) and culture medium as controls. A pool of 210 peptides (15-17-mer) overlapping
32 by 10 spanning the entire SARS-CoV-2 spike protein were synthesized and kindly provided by Dr.

1 Shengce Tao from Shanghai Jiao Tong University, China. Peptides were pretreated with 100 µg/mL
2 polymyxin B (Beyotime) for 30 min on ice before stimulation to exclude the LPS contamination.
3 Cytokine IFN-γ and IL-2 in the supernatants were detected using the corresponding ELISA Kits
4 according to the manufacturer's instruction (MultiSciences Biotech). A standard curve was
5 established according to the OD values, and antibody concentrations were calculated.

6

7 **Neutralization assay**

8 To determine the serum neutralization activity against GFP-expressing spike pseudovirus. Vaccinated
9 mouse serum (40×dilutions) were incubated with GFP-expressing spike pseudovirus at 37°C for 1 hr
10 before adding the mixtures to Huh-7 cells (4×10^4 cells per well in 48-well plates). The media were
11 changed after 12 hr and photos were taken at 48 hr post infection. For luciferase-encoding spike
12 pseudovirus neutralization assay. Serial dilutions of ShaCovacc or placebo vaccinated mouse serum
13 were incubated with luciferase-encoding pseudovirus at 37°C for 1 hr before adding to Huh-7 cells
14 (10^4 cells per well in 96-well plates). The culture media were refreshed 12 hr post-infection, which
15 was followed by an additional 48 hr incubation. Huh-7 cells were subsequently lysed with 50 µL lysis
16 reagent (Promega), and 30 µL lysates were transferred to 96-well Costar flat-bottom luminometer
17 plates (Corning Costar) for the detection of relative light units using the Firefly Luciferase Assay Kit
18 (Promega) with an Ultra 384 luminometer (Tecan). A nonlinear regression analysis was performed
19 on the resulting curves using Prism (GraphPad) to calculate half-maximal inhibitory concentration
20 (EC50) values.

21

22 **Immunofluorescence imaging**

23 293T cells were seed to 48-well plates with 0.1 mg/mL poly-D-lysine coated cover glasses at a density
24 of 4×10^4 /well. On the next day, cells were transduced by 150 ng IDLVs or VSPs, or transfected by
25 0.6 µg pCMV-spike-6XMS2 or pCMV-spike-mut-6XMS2 plasmids. Cells were fixed using 4%
26 paraformaldehyde 36 hr after transduction and transfection. Cells were then stained by anti-flag tag
27 antibody (Proteintech) followed by Alexa Fluor 555 IgG incubation (Cell Signaling Technology) and
28 nuclei staining with DAPI (Beyotime Biotechnology). The imaging was performed on a confocal
29 microscope (A1Si, Nikon) to verify the expression of Spike proteins.

30

31 **Statistics**

1 Data are presented as mean \pm S.D. in all experiments. One-way analysis of variance (ANOVA) or
2 student's t-tests were performed to determine the P values. *indicates statistical significance (*P<
3 0.05, **P< 0.01, ***P< 0.001, n.s.=non-significant).

4

5 **Data availability**

6 Data generated or analysed during this study are available from the corresponding author on
7 reasonable request.

8

9 **Acknowledgement**

10 Y.C. is supported by National Natural Science Foundation of China [31971364], Pujiang Talent
11 Project of Shanghai [GJ4150006], Shanghai Municipal Natural Science Foundation [BS4150002]
12 and Startup funding from Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University
13 [WF220441504]. J.H. is supported by the National Natural Science Foundation of China [81970766
14 and 81670818] and the Shanghai Rising-Star Program [18QA1401100]. T.Y. is supported by the
15 National Key R&D Program of China [2019YFA0904400] and National Natural Science Foundation
16 of China [81822027, 81630090].

17

18 **Conflict of interest**

19 The authors declare no conflict of interest.

20

21 **Author contribution**

22 D.Y., S.L., and Y.C. conceived the study and designed the experiments; D.Y., S.L., X.T., Y.L., Z.X.,
23 J.H., X.Z., X.W., and J.H. performed the experiments; all the authors analysed the data; D.Y., S.L.,
24 T.Y., and Y.C. wrote the manuscript with the help from all the authors.

25

26

27

28

1 REFERENCES

- 2 1. Wu, F., *et al.* A new coronavirus associated with human respiratory disease in China.
3 *Nature* **579**, 265-269 (2020).
- 4 2. Zhou, F., *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-
5 19 in Wuhan, China: a retrospective cohort study. *The Lancet* **395**, 1054-1062 (2020).
- 6 3. Zhang, J.-j., *et al.* Clinical characteristics of 140 patients infected with SARS-CoV-2 in
7 Wuhan, China. *Allergy n/a*(2020).
- 8 4. Richner, J.M., *et al.* Modified mRNA Vaccines Protect against Zika Virus Infection. *Cell* **169**,
9 176 (2017).
- 10 5. Pardi, N., *et al.* Zika virus protection by a single low-dose nucleoside-modified mRNA
11 vaccination. *Nature* **543**, 248-251 (2017).
- 12 6. Thanh Le, T., *et al.* The COVID-19 vaccine development landscape. *Nat. Rev. Drug Discov.*
13 **19**, 305-306 (2020).
- 14 7. Kim, E., *et al.* Microneedle array delivered recombinant coronavirus vaccines:
15 Immunogenicity and rapid translational development. *EBioMedicine* **0**, 102743 (2020).
- 16 8. Gao, Q., *et al.* Rapid development of an inactivated vaccine candidate for SARS-CoV-2.
17 *Science*, eabc1932 (2020).
- 18 9. Rappuoli, R., Pizza, M., Del Giudice, G. & De Gregorio, E. Vaccines, new opportunities for a
19 new society. *Proceedings of the National Academy of Sciences* **111**, 12288 (2014).
- 20 10. Plotkin, S.A. Vaccines: past, present and future. *Nat. Med.* **11**, S5-S11 (2005).
- 21 11. Pardi, N., Hogan, M.J., Porter, F.W. & Weissman, D. mRNA vaccines - a new era in
22 vaccinology. *Nat. Rev. Drug Discov.* **17**, 261-279 (2018).
- 23 12. Shang, W., Yang, Y., Rao, Y. & Rao, X. The outbreak of SARS-CoV-2 pneumonia calls for viral
24 vaccines. *npj Vaccines* **5**, 18 (2020).
- 25 13. Kushnir, N., Streatfield, S.J. & Yusibov, V. Virus-like particles as a highly efficient vaccine
26 platform: Diversity of targets and production systems and advances in clinical
27 development. *Vaccine* **31**, 58-83 (2012).
- 28 14. Noad, R. & Roy, P. Virus-like particles as immunogens. *Trends Microbiol.* **11**, 438-444
29 (2003).
- 30 15. Urakami, A., *et al.* Development of a Novel Virus-Like Particle Vaccine Platform That
31 Mimics the Immature Form of Alphavirus. *Clin. Vaccine Immunol.* **24**, e00090-00017 (2017).
- 32 16. Masavuli, M.G., Wijesundara, D.K., Torresi, J., Gowans, E.J. & Grubor-Bauk, B. Preclinical
33 Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C.
34 *Frontiers in Microbiology* **8**(2017).
- 35 17. Poh, C.M., *et al.* Potent neutralizing antibodies in the sera of convalescent COVID-19
36 patients are directed against conserved linear epitopes on the SARS-CoV-2 spike protein.
37 *bioRxiv*, 2020.2003.2030.015461 (2020).
- 38 18. Duan, K., *et al.* Effectiveness of convalescent plasma therapy in severe COVID-19 patients.
39 *Proceedings of the National Academy of Sciences*, 202004168 (2020).
- 40 19. Ju, B., *et al.* Potent human neutralizing antibodies elicited by SARS-CoV-2 infection. *bioRxiv*,
41 2020.2003.2021.990770 (2020).
- 42 20. Wu, F., *et al.* Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered
43 patient cohort and their implications. *medRxiv*, 2020.2003.2030.20047365 (2020).
- 44 21. Walls, A.C., *et al.* Structure, Function, and Antigenicity of the SARS-CoV-2 Spike
45 Glycoprotein. *Cell* **181**, 281-292.e286 (2020).

- 1 22. Pallesen, J., *et al.* Immunogenicity and structures of a rationally designed prefusion MERS-
2 CoV spike antigen. *Proceedings of the National Academy of Sciences* **114**, E7348 (2017).
- 3 23. Hu, B., Tai, A. & Wang, P. Immunization delivered by lentiviral vectors for cancer and
4 infectious diseases. *Immunol. Rev.* **239**, 45-61 (2011).
- 5 24. Chang, D. & Zaia, J. Why Glycosylation Matters in Building a Better Flu Vaccine. *Molecular
6 & Cellular Proteomics* **18**, 2348 (2019).
- 7 25. Watanabe, Y., Allen, J.D., Wrapp, D., McLellan, J.S. & Crispin, M. Site-specific glycan
8 analysis of the SARS-CoV-2 spike. *Science*, eabb9983 (2020).
- 9 26. Crawford, K.H.D., *et al.* Protocol and reagents for pseudotyping lentiviral particles with
10 SARS-CoV-2 Spike protein for neutralization assays. *bioRxiv*, 2020.2004.2020.051219
11 (2020).
- 12 27. Ying, T., *et al.* Exceptionally Potent Neutralization of Middle East Respiratory Syndrome
13 Coronavirus by Human Monoclonal Antibodies. *J. Virol.* **88**, 7796 (2014).
- 14 28. Prompetchara, E., Ketloy, C. & Palaga, T. Immune responses in COVID-19 and potential
15 vaccines: Lessons learned from SARS and MERS epidemic. *Asian Pac. J. Allergy Immunol.*
16 **38**, 1-9 (2020).
- 17 29. Zheng, H.-Y., *et al.* Elevated exhaustion levels and reduced functional diversity of T cells in
18 peripheral blood may predict severe progression in COVID-19 patients. *Cell. Mol. Immunol.*
19 **17**, 541-543 (2020).
- 20 30. Wang, Q., *et al.* Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.
21 *Cell*.
- 22
- 23
- 24

25 **Legends**

26 **Figure 1. Construct and characterization of a SARS-Cov-2 simulating particle vaccine. a,**
27 Construction of mRNA-encoding plasmid which transcribes a MS2 stem loop-containing spike
28 mRNA. The spike mRNA and protein will be packaging into lentiviral particles via the RNA-coat
29 protein interaction and self-assembly, respectively. NTD, N-terminal domain; RBD, receptor binding
30 domain; SD1 and SD2, subdomain 1 and 2; FP, fusion peptide; HR1 and HR2, heptad repeat 1 and 2;
31 TM, transmembrane domain; CT, cytoplasmic tail. **b,** Illustration of the production process of the
32 SARS-CoV-2 vaccine using VSP platform. **c,** Copy number of spike mRNA in each VSP particle.
33 The copy number was detected by absolute quantification RT-qPCR and normalized to IDLV-spike-
34 mut (2 copies RNA per virion). **d,** Western blot analysis of the spike protein in the virion treated
35 with/without PNGase F. IDLV use as a control. 100 ng p24 for each vector. **e,** Western blot analysis
36 of the spike protein expression. 293T cells were collected 36 hr after transfection or transduction. 300
37 ng p24 virus for each well. **f,** Confocal analysis of spike protein expression. 293T cells were fixed 36
38 hr after transfection or transduction. **g-i,** Innate immune response induced by VSP in THP-1 derived

1 macrophages. Cells were harvested for IFNB1, ISG15 and RIG-I analysis by RT-qPCR 6 hr after
2 transduction 150 ng p24 per well for each virus and 1.5 µg poly I:C per well as positive controls. S
3 represents spike. One-way ANOVA with Dunnett's *post hoc* tests were performed, ***P< 0.001,
4 n.s.=non-significant.

5
6 **Figure 2. Analysis of neutralizing activity of sera from ShaCoVacc vaccinated mice and linear**
7 **epitope profiling with peptide microarray.** **a**, Illustration of the working plan. The sera and
8 splenocytes were collected 14 days after footpad ShaCoVacc injection for further analysis. **b**, ELISA
9 analysis of spike specific IgG. **c** and **d**, Neutralization activity of vaccinated sera evaluated by
10 luciferase assay and confocal microscopy. A firefly luciferase-encoding and GFP-expressing SARS-
11 CoV2 pseudovirus was used, respectively, to transduce Huh-7 cells. **e** and **f**, Evaluation of the spike-
12 specific cellular immune response stimulating with a spike peptide pool. **g-i**, Peptide microarray
13 analysis of epitopes. **g**, Representative images of spike protein peptide microarray. S1 protein and
14 RBD were included in the microarray as controls. Highly frequent positive peptides were labeled. **h**.
15 Antibody responses against S1 protein or RBD in vaccinated mice. Signal intensity was averaged
16 fluorescent intensity of tinplated spots for each array. **i** Heatmap of antibody responses against
17 peptides. Gray grid indicates negative response. **j**, Analysing the epitopes of ShaCoVacc induced
18 spike-specific antibodies on spike protein. 6 mice used for each group, 1.5 µg ShaCoVacc or 50 µL
19 PBS were injected via footpad into each mouse. Error bars represent ±S.D. Unpaired two-tailed
20 student's t-tests (**b**, **c** and **h**), *P<0.05, ***P< 0.001.

21

Figure 1




Figure 2

